Brahim MOJEMMI

Prof. Brahim MOJEMMI

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2024 in Journal of Traditional and Complementary Medicine
Verified
Journal Article
Open access
RJRania Jerada
Rania Jerada
AEAbdeljalil Er-Rakibi
Abdeljalil Er-Rakibi
AHAbha Cherkani Hassani
Abha Cherkani Hassani
HBHanane Benzeid
Hanane Benzeid
AOAbdelmoula El Ouardi
Abdelmoula El Ouardi
ADAnass Doukkali
Anass Doukkali
Dittrichia viscosa is a perennial herb that has been used for generations in traditional medicine to address a variety of diseases, including diabetes, hypertension, cancer, microbial disorders, inflammatory conditions, and wound healing. The objective of this review is to provide an overview of existing knowledge on D. viscosa with regards to its botanical description, ethnomedicinal uses, and pharmacological properties. Databases such as Scopus, Wiley-Online, PubMed, Springer, Google Scholar, and ScienceDirect were used to select relevant articles based on their title and

1 December 2021 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
ACAbha Cherkani-Hassani
Abha Cherkani-Hassani
MSMeriem Slaoui
Meriem Slaoui
IGImane Ghanname
Imane Ghanname
BMBrahim MOJEMMI
Brahim MOJEMMI
ABAbdelilah Belhaj
Abdelilah Belhaj
NMNezha Mouane
Nezha Mouane

18 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
LYLamyae Yachi
Lamyae Yachi
BMBrahim MOJEMMI
Brahim MOJEMMI
KKKhalid Karrouchi
Khalid Karrouchi
MBMustapha Bouatia
Mustapha Bouatia
Background: Elemental impurities (EIs) in pharmaceutical products may originate from active pharmaceutical ingredients, excipients, manufacturing equipment, utilities, and packaging materials. The ICH Q3D guideline provides a risk-based framework for evaluating and controlling these impurities according to their permitted daily exposure (PDE). This study aimed to perform a comprehensive assessment of elemental impurity risks in an oral solid dosage form using the ICH Q3D component approach (Option 2b), complemented by a quality risk assessment of manufacturing equipment. Methods: The elemental impurity risk assessment was performed using the component approach (Option 2b), considering the active pharmaceutical ingredient (API), four pharmaceutical excipients, manufacturing equipment, primary packaging, and purified water. Supplier data and available analytical results were used to estimate the daily contribution of Class 1 elements (Cd, Pb, As, and Hg) and Class 2A elements (Co, V, and Ni). The calculated patient exposure was compared with the corresponding oral PDE values established by ICH Q3D. Manufacturing equipment was additionally evaluated using Failure Mode and Effects Analysis (FMEA) to identify potential failure modes and assess the effectiveness of existing control measures. Results: The API showed consistently low concentrations of the investigated elemental impurities, with values ≤0.1 µg/g across three independent batches. The assessment of the four excipients indicated no intentional addition of the investigated elemental impurities and low overall contributions to patient exposure. Manufacturing equipment presented a negligible residual risk following the implementation of GMP controls, including equipment qualification, cleaning procedures, preventive maintenance, and visual inspection. The estimated total daily exposures were 0.27, 0.27, 0.27, 0.28, 0.29, 0.32, and 1.66 µg/day for Cd, Pb, As, Hg, Co, V, and Ni, respectively. These values corresponded to 5.4%, 5.4%, 1.8%, 0.9%, 0.58%, 0.32%, and 0.83% of their respective PDEs, all remaining well below the 30% PDE threshold used for the control strategy. Primary packaging and purified water were also considered negligible contributors. Conclusion: The ICH Q3D component approach (Option 2b), combined with systematic quality risk management of manufacturing equipment, provided a practical and scientifically justified framework for elemental impurity assessment in the investigated oral solid dosage form. The estimated exposures were substantially below the applicable PDE values, supporting the adequacy of the existing control measures and indicating that no additional elemental impurity-specific controls were required. This approach may support efficient risk-based decision-making and routine pharmaceutical quality management when reliable supplier and process data are available.